Cancer represents an evolutionary process through which growing malignant populations
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …

Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is
a clinically and genetically heterogeneous disease that is further classified into …

PURPOSE In previous analyses of the MURANO study, fixed-duration venetoclax plus
rituximab (VenR) resulted in improved progression-free survival (PFS) compared with …

Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an
aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics …

Summary Background Therapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has
transformed the treatment of chronic lymphocytic leukaemia. However, patients who are …

Defining the transcriptomic identity of malignant cells is challenging in the absence of
surface markers that distinguish cancer clones from one another, or from admixed non …

Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …

Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has
emerged as a transformative treatment option for patients with chronic lymphocytic leukemia …